EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways

XIAO-GUANG LV*, MENG-YAO JI*, WEI-GUO DONG, XIAO-FEI LEI, MENG LIU, XU-FENG GUO, JING WANG and CHUO FANG

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

Received November 18, 2011; Accepted February 17, 2012

DOI: 10.3892/mmr.2012.805

Abstract. 5-Fluorouracil (5-FU) plays an important role in the chemotherapy of advanced gastric cancer. However, genetic factors that affect therapeutic efficacy of 5-FU warrant further investigation. In the present study, using stable transfection of the ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) gene, we explored the genetic influences on 5-FU-induced apoptosis of human gastric cancer cells. Stable overexpression of the EBP50 gene was determined by reverse transcription polymerase chain reaction (RT-PCR) assay and western blot analysis. After treatment with 5-FU, cell growth activities in vitro were investigated by MTT assay. Cell apoptosis was evaluated by Hoechst 33258 staining and flow cytometry of Annexin V-FITC/PI staining. Compared with the BGC823 or BGC823/neo cells, EBP50 mRNA and protein levels in the BGC823/EBP50 cells (EBP50-transfected BGC823 cells) were markedly higher. Chemosensitivity and apoptosis rates of the BGC823/EBP50 cells were higher compared to the BGC823 and BGC823/neo cells following treatment with 5-FU. Stable overexpression of extrinsic EBP50 distinctly increases the 5-FU-induced apoptosis of gastric cancer cells, and is a novel strategy by which to improve the chemosensitivity of gastric cancer to 5-FU.

Introduction

Gastric cancer is an extremely common disease worldwide and is the second most frequent cause of cancer-related death, affecting approximately one million individuals per year. The highest incidence, 69 cases per 100,000 people annually, is found in males of Northeast Asia (Japan, Korea, and China) (1). Preoperative or neoadjuvant chemotherapy potentially downstages advanced gastric cancer and improves resectability and survival.

A significant survival benefit of 5-fluorouracil (5-FU)–based chemotherapy for metastatic gastric cancer compared with best supportive care has been reported (2,3). In Western countries, 5-FU combined with cisplatin and cisplatin plus epirubicin have been referred to as the standard chemotherapy for metastatic gastric cancer, with a median survival rate ranging from 7.3 to 10.5 months (2). In China, 5-FU monotherapy still remains the reference arm of clinical trials for metastatic gastric cancer (3). Combined surgery and chemotherapy with 5-FU/cisplatin, is considered as the standard therapy for advanced gastric cancer. At present, 5-FU is one of the most commonly used chemotherapeutic agents. Despite these advances, drug resistance remains a problem in regards to the clinical use of 5-FU. With the advent of novel technologies, specific genes have been identified to be involved in mediating resistance to 5-FU (4). It is important to clarify the molecular mechanisms linked to the chemosensitivity of 5-FU.

Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is a post synaptic density-95/Disk-large/ZO-1 homologous domain-containing protein that is involved in the linkage of integral membrane proteins to the cytoskeleton and plays an important role in cell signaling (5). Overexpression of NHERF1/EBP50 has been reported in breast cancer (5,6) and in 55% of hepatocellular carcinoma samples (7). Initially, overexpression of NHERF1/EBP50 has been correlated with lower tumor invasiveness in breast cancer cell lines (8). These two independent studies however reached the same conclusions. They found that EBP50 overexpression is significantly associated with tumor stage, metastatic progression, poor prognosis and ER status (5,9). The expression and distribution of EBP50 are regulated by estrogens and contribute to the proliferative response in biliary epithelial cells (10). We discovered that EBP50 is a novel marker for gastric adenocarcinoma and is involved in the proliferation, migration, and invasion of gastric cancer cells. Little attention has been paid, however, to the relationship between EBP50 and 5-FU chemosensitivity.

In the present study, we investigated whether EBP50 plays a role in 5-FU-induced apoptosis in gastric cancer cells. To test
Cells were collected, washed twice with cold PBS, and resuspended with 100 µl binding buffer into 5x10^5 cells/ml, and incubated with Annexin V-FITC at room temperature for 15 min. After washing with a binding buffer, the cells were resuspended with 500 µl binding buffer containing 10 µl PI (20 µg/ml), and incubated on ice for 30 min. Apoptosis was analyzed by flow cytometry at a wavelength of 488 nm. For each detection, the total procedure was repeated 3 times.

**Western blot analysis.** Levels of protein expression were analyzed by western blot analysis. Briefly, cells were washed with PBS and lysed in lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 50 µg/ml leupeptin, 30 µg/ml aprotinin and 1 mM PMSF). A total volume of 40 µg of protein was loaded per lane and separated on 12.5% sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels and then transferred to a nitrocellulose membrane (Millipore Corp., Bedford, MA, USA) using wet transfer system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membrane was blocked with 10% nonfat dry milk in TBST and then incubated with the following primary antibodies: procaspase-9, cleaved caspase-9, procaspase-3, cleaved caspase-3, and GADPH (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4°C. The following dilutions were used: procaspase-9 (1:1,000), procaspase-3 (1:1,000), cleaved caspase-9 (1:1,000), cleaved caspase-3 (1:1,000), Bax (1:2,000), Bcl-2 (1:3,000) and actin (1:1,000). After three washes with TBST, the membranes were incubated with biotinylated goat anti-rabbit IgG secondary antibody (Promega Corp., Madison, WI, USA; 1:3,000 dilution) for 1 h at room temperature and then developed with the use of an enhanced chemiluminescence (ECL) system (Millipore) and then exposed to Kodak X-ray film (Kodak, Rochester, NY, USA). Protein band intensities were determined densitometrically using the video imaging CMIASWIN system (Bio-Rad).

**Statistical analyses.** All data are expressed as means ± SD. The means of the different groups were compared using one-way ANOVA test. All statistical analyses were performed with SPSS13.0 software (SPSS, Inc., Chicago, IL, USA). Significant differences were accepted at P-values <0.05.

**Results**

**Construction of the pBK-CMV-HA-EBP50 vector and over-expression of EBP50 in BGC823 cells.** The recombinants, pBK-CMV-HA-EBP50, were validated by DNA-sequencing analysis and restriction-endonuclease analysis. All untransfected BGC823 cells were dead after G418 (200 µg/ml) selection for 1 week. The pBK-CMV-HA-EBP50-transfected cells were continuously selected with G418 for 4 weeks, until magnificent clones were observed. The clones were respectively amplified. The subclone BGC823/neo cells and BGC823/EBP50 cells were obtained. To investigate the mRNA and protein expression of EBP50 in the BGC823, BGC823/neo and BGC823/EBP50 cells, the levels of EBP50 were measured by RT-PCR assay and western blot analysis. The relative expression of EBP50 to actin is shown. The mRNA and protein levels of EBP50 in the BGC823/EBP50 cells were significantly greater than levels in the BGC823 and BGC823/neo cells (P<0.05). No difference was noted between
the BGC823 and BGC823/neo cells in terms of the brightness of the EBP50 bands (P>0.05) (Fig. 1A and B).

Cellular sensitivity to 5-FU. To study cellular sensitivity to 5-FU, BGC823, BGC823/neo and BGC823/EBP50 cells were exposed to various concentrations (0.1, 1.0 and 10.0 mg/l) of 5-FU for different durations (0, 12 and 24 h). Rates of cellular growth inhibition were measured by MTT assay. As shown in Fig. 1C, overexpression of EBP50 promoted the inhibition of the cellular growth rate in the BGC823/EBP50 cells compared with these values in the BGC823 and BGC823/neo cells. No difference in growth inhibitory rates between BGC823 and BGC823/neo cells were noted (P>0.05).

Overexpression of EBP50 enhances 5-FU-induced apoptosis and its mechanism in BGC823 cells. BGC823, BGC823/neo and BGC823/EBP50 cells were exposed to 5-FU for various durations (0, 12 and 24 h). First, morphological changes indicative of apoptosis such as chromatin condensation and nuclear fragmentation were analyzed by Hoechst 33258 staining assay (Fig. 2A). We found that the overexpression of EBP50 induced a higher percentage of cell apoptosis in BGC823/EBP50 cells (12 h, 12.9±7.8%; 24 h, 27.8±5.1%) than these values in BGC823 (12 h, 8.6±3.6%; 24 h, 17.4±6.5%), and BGC823/neo cells (12 h, 7.4±6.4%; 24 h, 17.3±3.5%) (Fig. 2B). Subsequently, Annexin V-FITC/PI staining was performed and flow cytometry was carried out, which further confirmed that overexpression of EBP50 enhanced 5-FU-induced apoptosis. We observed that overexpression of EBP50 induced a higher percentage of cell apoptosis in the BGC823/EBP50 cells (12 h, 12.9±7.8%; 24 h, 27.8±5.1%) compared to the percentage of cell apoptosis in the BGC823 (12 h, 9.7±2.7%; 24 h, 17.8±4.6%) and BGC823/neo cells (12 h, 8.3±3.5%; 24 h, 24.0±7.8%) (Fig. 3).
Role of Bcl-2, Bax, and caspase activity in EBP50-enhanced 5-FU-induced apoptosis. We performed a subsequent study to explore the potential mechanism involved in EBP50-enhanced 5-FU-induced apoptosis. Activation of Bax, Bcl-2, cleaved forms of caspase-3 and -9 were detected by western blot analysis. Compared with BGC823 and BGC823/neo cells, the activity of Bax, caspase-3 and -9 in BGC823/EBP50 cells treated with 5-FU were highly upregulated (P<0.05) (Fig. 4). These results suggest that overexpression of EBP50 enhances the activity of caspase-3 and -9.

Discussion

Gastric cancer is still the second leading cause of cancer-related death worldwide. Chemotherapy is one of the major treatment options for advanced gastric cancer (1). The efficacy of chemotherapy for cancer is poor due to insensitivity and the development of drug resistance. Serious challenges lay ahead given the complex nature of the cytotoxic metabolism with multiple players working together to influence a drug's effectiveness and toxicity (11). The combined use of molecular-targeted therapy with chemotherapy, however, may provide new opportunities for cancer treatment (12,13). The identification of molecules within an apoptotic pathway will potentiate tumor chemosensitivity that may ultimately enable the optimization of chemotherapy for cancer by enhancing a therapeutic response to chemotherapy and modulating the apoptotic threshold of cancer cells (14,15).

In the present study, the EBP50 gene was transfected into human gastric cancer cell lines, which induced its over-
expression. We found that EBP50 overexpression enhanced the apoptosis-inducing effects of 5-FU by MTT assay and Annexin V-FITC/PI staining and flow cytometry. EBP50 gene transfection resulted in the activation of caspase-3 and -9 in the BGC823 cells, indicating that mitochondrial dysfunction may be involved in EBP50-induced suppression.

The human Bcl-2 gene, located on chromosome 18, is a proto-oncogene in the hematopoietic system (16). The Bcl-2 gene suppresses apoptosis induced by many other factors (17) and the Bax gene encodes a 21-kDa protein, and has 21% homology with the Bcl-2 gene (18). Overexpression of the Bax gene inhibits the function of Bcl-2 and promotes apoptosis (19). Caspases are crucial mediators of apoptosis. Among them, caspase-3 and -9 are frequently activated death protease, catalyzing specific cleavage of many key cellular proteins. Caspase-3 may be the best understood mammalian caspase in terms of its specificity and role in apoptosis (20).

In the BGC823 cells transfected with the EBP50 gene, the

Figure 3. (A) Cellular apoptosis was analyzed by flow cytometry in BGC823/neo and BGC823/EBP50 cells. Annexin/PI staining was performed. The rate of apoptotic cells was defined as the sum of the number of cells in the upper right quadrant and lower right quadrant (n=5). (B) Data are expressed as the mean ± SE. (P<0.05; #P>0.05).
of colorectal cancer. This approach may allow for an effective clinical application of chemogene therapy. Treatment with a combination of adenovirus-EBP50 and 5-FU warrants further investigated and may conceivably be beneficial for gastric cancer patients.

In conclusion, we found that EBP50 overexpression enhances the apoptotic effects induced by 5-FU, although mitochondrial dysfunction may be involved in EBP50-induced suppression in gastric cancer cells. These results indicate that a combination of adenovirus-EBP50 and 5-FU may be applied to treat gastric cancer in the future.

Acknowledgements

This study was supported by the Fundamental Research Funds for the Central University of China (no. 20103020101000194).

References


expression of Bcl-2 protein was downregulated while Bax was upregulated (Fig. 4B). Subsequently, EBP50 may regulate the death-receptor-associated extrinsic caspase-8 pathway, resulting in the activation of the mitochondria-associated intrinsic caspase-9 pathway in BGC823 cells. The result may be a co-operative activation of executioner caspase-3 by both caspase pathways in the end. In agreement with our hypothesis, activated caspase-3 and -9 were detected in BGC823 cells transfected with the EBP50 gene in each group (Fig. 4A).

Chemogene therapy has been a viable alternative to conventional chemotherapy combinations for cancer. Chemogene therapy is effective due to the sensitizing of tumor cells to apoptosis by overexpression of a pro-apoptotic protein, followed by the administration of lower doses of chemotherapeutic drugs, therefore reducing systemic toxicity (21,22). Choi et al (23) found that the combination of adenoviral-mediated IFN-β gene therapy and 5-FU resulted in tumor regression, apoptosis, and improved survival in an established liver metastasis model


